Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbetsgemeinschaft für Pädiatrische Nephrologie"
- PMID: 84259
Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbetsgemeinschaft für Pädiatrische Nephrologie"
Abstract
23 children with frequently relapsing minimal-change nephrotic syndrome were treated with alternate-day prednisone (35 mg/m2/48 h) and 25 other patients were treated with intermittent prednisone (40 mg/m2 on three consecutive days out of seven) for six months. This was followed by six months without any maintenance steroid treatment except when relapse required a short period of prednisone therapy until remission. The number of relapsers was significantly lower on alternate-day than on intermittent treatment. In the alternate-day group, the number of relapsers and the rate of relapse was significantly less before treatment withdrawal; in the intermittent group, only the number of relapsers was reduced. An alternate-day regiment is therefore preferable to the intermittent regimen in the interrupted steroid treatment of children with nephrotic syndrome.
Similar articles
-
Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie.Lancet. 1988 Feb 20;1(8582):380-3. Lancet. 1988. PMID: 2893190 Clinical Trial.
-
Alternate-day prednisone is more effective than intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbeitsgemeinschaft für Pädiatrische Nephrologie.Eur J Pediatr. 1981 Feb;135(3):229-37. doi: 10.1007/BF00442096. Eur J Pediatr. 1981. PMID: 7227377 No abstract available.
-
Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie.Eur J Pediatr. 1993 Apr;152(4):357-61. doi: 10.1007/BF01956754. Eur J Pediatr. 1993. PMID: 8482290 Clinical Trial.
-
Chlorambucil treatment of frequently relapsing nephrotic syndrome.N Engl J Med. 1976 Sep 30;295(14):746-9. doi: 10.1056/NEJM197609302951402. N Engl J Med. 1976. PMID: 958261 Clinical Trial.
-
Management of minimal lesion glomerulonephritis: evidence-based recommendations.Kidney Int Suppl. 1999 Jun;70:S3-16. doi: 10.1046/j.1523-1755.1999.07002.x. Kidney Int Suppl. 1999. PMID: 10369190 Review.
Cited by
-
The non-immunosuppressive management of childhood nephrotic syndrome.Pediatr Nephrol. 2016 Sep;31(9):1383-402. doi: 10.1007/s00467-015-3241-0. Epub 2015 Nov 10. Pediatr Nephrol. 2016. PMID: 26556028 Free PMC article. Review.
-
How randomised trials have improved the care of children with kidney disease.Pediatr Nephrol. 2016 Dec;31(12):2191-2200. doi: 10.1007/s00467-016-3455-9. Epub 2016 Aug 3. Pediatr Nephrol. 2016. PMID: 27488519 Review.
-
Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome.Pediatr Nephrol. 2022 Jan;37(1):37-47. doi: 10.1007/s00467-021-04985-1. Epub 2021 Feb 20. Pediatr Nephrol. 2022. PMID: 33611671 Free PMC article. Review.
-
Human leucocyte antigens in idiopathic nephrotic syndrome in children.Pediatr Nephrol. 1990 Sep;4(5):478-81. doi: 10.1007/BF00869824. Pediatr Nephrol. 1990. PMID: 2242309
-
Evidence-based management of steroid-sensitive nephrotic syndrome.Pediatr Nephrol. 2005 Nov;20(11):1523-30. doi: 10.1007/s00467-005-1968-8. Epub 2005 Jun 21. Pediatr Nephrol. 2005. PMID: 15968558 Review.